Boehringer Ingelheim’s Lung Cancer Drug Gets Fast-Track Status

Boehringer Ingelheim’s investigational nonsmall cell lung cancer or NSCLC treatment BIBW 2992 has received fast track designation status from the FDA.
Pharmaceutical Business Review